Clinical trial
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or…
NCT00244985 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00244985 |
|---|---|
| Title | Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase I/II Pilot Study of the Safety and Efficacy of Rituxan (Chimeric Anti-CD20 Antibody) in Combination With Doxil (Liposomal Doxorubicin) Chemotherapy in Patients With Relapsing or Refractory Indolent or Aggressive B-Cell Lymphoma |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | Ortho Biotech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 42 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Dec 1, 2012 |
| First posted | Oct 27, 2005 |
| Last update posted | Aug 17, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: